Data / Drug companies / Actavis Pharma, Inc.
Actavis Pharma, Inc.: 10 products in the FDA NDC directory, labeler code 62037
Actavis Pharma, Inc. (labeler code 62037) lists 10 products in the FDA National Drug Code Directory, covering 3 finished drugs by generic name. By type: 9 prescription drugs, 1 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 4, 2019.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62037
- Products in commercial distribution
- 10
- Packages
- 15
- Finished drugs by generic name
- 3
- Prescription products
- 9
- Over the counter products
- 0
- Controlled substance products
- Schedule II 4
- Flagged as original packager
- 5 of 5 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- July 9, 1998
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 9 | 90% |
| Drugs for further processing | 1 | 10% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 9 | 90% |
| Drugs for further processing | 1 | 10% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Methylphenidate hydrochloride | 4 | 39 |
| Diltiazem hydrochloride | 4 | 55 |
| Potassium chloride | 1 | 84 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated, extended release | 4 | 40% |
| Capsule, extended release | 4 | 40% |
| Tablet, extended release | 2 | 20% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Central Nervous System Stimulant | 4 |
| Calcium Channel Blocker | 4 |
| Osmotic Laxative | 1 |
| Potassium Salt | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Methylphenidate Hydrochloride | 62037-734 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 4, 2019 |
| Methylphenidate Hydrochloride | 62037-727 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 4, 2019 |
| Methylphenidate Hydrochloride | 62037-726 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 4, 2019 |
| Methylphenidate Hydrochloride | 62037-725 | Tablet, film coated, extended release | Generic drugs (ANDA) | March 4, 2019 |
| Loratadine and pseudoephedrine sulfate | 62037-605 | Tablet, extended release | Drugs for further processing | February 21, 2003 |
| Potassium Chloride | 62037-720 | Tablet, extended release | Generic drugs (ANDA) | April 10, 2002 |
| Cartia XT | 62037-600 | Capsule, extended release | Generic drugs (ANDA) | July 9, 1998 |
| Cartia XT | 62037-599 | Capsule, extended release | Generic drugs (ANDA) | July 9, 1998 |
| Cartia XT | 62037-598 | Capsule, extended release | Generic drugs (ANDA) | July 9, 1998 |
| Cartia XT | 62037-597 | Capsule, extended release | Generic drugs (ANDA) | July 9, 1998 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.